Nanobiotix S.A. (5NR)
XDUS
Closed
Aug 25, 2026
Day's Range
33.8452 wk Range
7.16Overview - 5NR - Nanobiotix S.A.
Key Statistics
Valuation
Enterprise Value
42.56M
EV / EBITDA
‪-4.81‬
Profitability
Operating Margin
‪-45.75%‬
Return on Assets
‪-35.36%‬
Return on Equity
‪28.36%‬
Ownership
Shares Outstanding
48.38M
Price stats
50-Day Avg
‪33.11‬
200-Day Avg
‪26.72‬
Peers - 5NR - Nanobiotix S.A.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+86.04%52-week change-2.59P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.40%52-week change-45.96P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.08%52-week change-22.38P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.03%52-week change—P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+75.21%52-week change-0.06P/E (Trailing)—Profit Margin
Profile Summary - 5NR - Nanobiotix S.A.
About
Nanobiotix S.A. is a late-stage clinical biotechnology company specializing in physics-based nanomedicines to revolutionize cancer treatment. Headquartered in Paris, France, with offices in the United States, it pioneers nanotechnology that enhances radiotherapy's efficacy. The company's lead candidate, NBTXR3…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
